Chunghwa Chemical Synthesis & Biotech Co., Ltd. (1762.TW)

TWD 33.25

(-1.77%)

Market Cap (In TWD)

2.57 Billion

Revenue (In TWD)

2.08 Billion

Net Income (In TWD)

264.9 Million

Avg. Volume

243.65 Thousand

Currency
TWD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
32.9-58.2
PE
-
EPS
-
Beta Value
0.713
ISIN
TW0001762003
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Chung-Hsin Huang
Employee Count
-
Website
https://www.ccsb.com.tw
Ipo Date
2010-12-20
Details
Chunghwa Chemical Synthesis & Biotech Co., Ltd. engages in the research, development, manufacture, and wholesale of active pharmaceutical ingredients (APIs) in Taiwan and the United States. It offers API products, which include immunosuppressant, oncology, cardiovascular, and other products, as well as peptide drugs. The company also develops bulk pharmaceutical products, such as anti-anxiety agents, antidiabetics, laxatives, antifungals, antihistamines, antiseptics, antiulcerants, cardiovascular drugs, skeletal, muscle relaxants, hypolipaemics, antineoplastic, antihyperlipedemias, and immunosuppressant products, as well as provides research and development, and contract manufacturing services to new drug developers and generic drug companies. The company was formerly known as China Chemical Synthesis Industry Co., Ltd. Chunghwa Chemical Synthesis & Biotech Co., Ltd. was founded in 1964 and is headquartered in New Taipei City, Taiwan.